Clinical trials: Synucleinopathies
Parkinson Disease
Combining VNS With PT Interventions for Individuals With PD
The purpose of this study is to evaluate the combined effects of non-invasive neuromodulation (specifically transauricular Vagus Nerve Stimulation) with exercise interventions to improve physical function and quality of life in…
- Trial name
- VNS-PT-PD (NCT05871151)
- Testing
- taVNS, Exercise
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Alabama at Birmingham
Parkinson's Disease
A Pilot Study of Oxaloacetate in Subjects With Treated PD
The purpose of this study is to determine if Oxaloacetate (OAA) is a safe and effective treatment for Parkinson's disease. Each subject will be asked to make 3 study visits and complete two safety follow-up phone calls over a 4…
- Trial name
- NCT01741701
- Testing
- Oxaloacetate (OAA)
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Kansas Medical Center
Parkinson's Disease
Effects of Combined rTMS and Treadmill Training in People With Parkinson's Disease
The purpose of this study is to investigate whether the beneficial effect of treadmill training on people with Parkinson's disease can be enhanced by high- and low-frequency repetitive transcranial magnetic stimulation (rTMS).
- Trial name
- NCT02701647
- Testing
- Repetitive transcranial magnetic stimulation (rTMS), Treadmill training
- Where
- Hong Kong
- Volunteers
- 51 people
- Sponsor
- The Hong Kong Polytechnic University
Idiopathic Parkinson's Disease
Change in Gastrointestinal Complaints After Switch From Oral Parkinson's Disease Treatment to Neupro® Transdermal Patch
The study intends to collect data on gastrointestinal symptoms (swallowing disorders, heartburn, feeling of fullness, nausea, vomiting, abdominal pain, diarrhea) and on patient satisfaction under everyday practice conditions…
- Trial name
- NON-GI (NCT01159691)
- Where
- 21 sites in Germany
- Volunteers
- 76 people
- Sponsor
- UCB Pharma GmbH
Diabetic Retinopathy, Macular Degeneration
Advancing Understanding of Transportation Options
This Stage II randomized, controlled, longitudinal trial seeks to assess the acceptability, feasibility, and effects of a driving decision aid use among geriatric patients and providers.
- Conditions
- Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa
- Trial name
- AUTO (NCT04141891)
- Testing
- Driving Decision Aid, Older Drivers Website
- Where
- 3 sites in United States
- Volunteers
- 529 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Parkinson Disease, Early Parkinson's Disease
A Phase 3 Study With P2B001 in Subjects With Early Parkinson's
P2B001 is an investigational drug that comprised of low doses of two drugs, pramipexole and rasagiline, which are both approved drugs and routinely used in standard therapy for Parkinson's disease.
- Trial name
- NCT03329508
- Testing
- P2B001 0.6/0.75 mg, Rasagiline 0.75 mg, Pramipexole 0.6 mg
- Where
- 72 sites in United States, Canada and 2 more
- Volunteers
- 544 people
- Sponsor
- Pharma Two B Ltd.
Parkinson's Disease
Pioglitazone in Early Parkinson's Disease
This is a multi-center, double-blind, placebo controlled clinical trial of two dosages of oral pioglitazone (15 milligram(mg) and 45 milligram (mg)) for safety, tolerability, and futility.
- Trial name
- NCT01280123
- Testing
- Pioglitazone
- Where
- 38 sites in United States
- Volunteers
- 210 people
- Sponsor
- University of Rochester
Parkinson's Disease
Adaptive Closed Loop Neuromodulation and Neural Signatures of Parkinson's Disease
Continuous deep brain stimulation (cDBS) is an established therapy for the major motor signs in Parkinson's disease. Currently, cDBS is limited to "open-loop" stimulation, without real-time adjustment to the patient's state of…
- Trial name
- aDBS (NCT02384421)
- Testing
- Adaptive DBS (Activa PC+S Neurostimulator), Continuous DBS (Activa PC+S Neurostimulator)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Stanford University
Parkinson Disease, Mild Cognitive Impairment
Mild Cognitive Impairment and Endurance Exercise in Parkinson's Disease
The overall objective of this study is to determine how high intensity endurance exercise affects both cognition and the signs and symptoms of Parkinson's disease as well as if certain brain structures and functions also change…
- Trial name
- NCT03542474
- Testing
- High Intensity Endurance Exercise
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Northwestern University
Parkinson's Disease
Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease
Levodopa is the main drug treatment for Parkinson's disease. Levodopa can cause unwanted and uncontrolled movements called dyskinesias. A drug called amantadine can reduce these movements.
- Trial name
- NCT00794313
- Testing
- Amantadine 300 mg, Topiramate, Sugar Pill
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Oregon Health and Science University
Parkinson's Disease
Acute Effects of Medium Chain Triglyceride (MCT) Nutritional Ketosis on Parkinson's Disease (PD) Symptoms and Biomarkers (MCT-PD)
Background: The ketogenic diet uses fats as a person's major energy source rather than carbohydrates. There is increasing interest in using this diet to treat neurodegenerative disorders like Parkinson's disease.
- Trial name
- NCT04584346
- Testing
- Liquigen MCT oil, Standard American Diet
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Dystonia-Parkinsonism, Adult-Onset, Parkinson Disease
Unlocking Dystonia From Parkinson's Disease With Directional DBS Technology
This study occurs during five visits that are already scheduled as part of "Biomarkers to Guide Directional DBS for Parkinson's Disease" (ClinicalTrials.gov Identifier: NCT03353688).
- Trial name
- NCT03409120
- Testing
- Boston Scientific Vercise PC IPG with directional DBS lead
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Alabama at Birmingham
Parkinson's Disease
Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease
The objective of this open-label extension is to assess the long-term effect of the 24-hour transdermal delivery of rotigotine on motor function, sleep quality, and nocturnal and non-motor symptoms of Parkinson's disease.
- Trial name
- NCT00519532
- Testing
- Rotigotine
- Where
- 21 sites in United States, Australia and 9 more
- Volunteers
- 84 people
- Sponsor
- UCB Pharma
Dyskinesia, Levodopa Induced Dyskinesia (LID)
ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)
This is a multi-center, randomized, double-blind, placebo-controlled, 2-arm, parallel group study to evaluate the efficacy and safety of ADS-5102 extended release (ER) capsules, an investigational formulation of amantadine, dosed…
- Conditions
- Dyskinesia, Levodopa Induced Dyskinesia (LID), Parkinson's Disease
- Trial name
- EASE LID (NCT02136914)
- Testing
- ADS-5102
- Where
- 46 sites in United States, Canada
- Volunteers
- 126 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
Parkinson Disease, Autonomic Dysfunction
Investigating Central Neurophysiologic Correlates of Non-Motor Symptoms of Parkinson's Disease
This is a randomized, single-blinded, triple crossover study focused on determining the feasibility of using transcranial magnetic stimulation (TMS) for treatment of Parkinson's disease related autonomic dysfunction and…
- Conditions
- Parkinson Disease, Autonomic Dysfunction, Depression
- Trial name
- NCT05205772
- Testing
- transcranial magnetic stimulation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of North Carolina, Chapel Hill
Parkinson Disease
A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment
This study will evaluate the safety, tolerability, and potential effects on cognition of GRF6021, a plasma-derived product, administered as an intravenous (IV) infusion, to subjects with Parkinson's disease and cognitive…
- Trial name
- NCT03713957
- Testing
- GRF6021
- Where
- 29 sites in United States, Australia and 1 more
- Volunteers
- 79 people
- Sponsor
- Alkahest, Inc.
Parkinson Disease
Cognitive Training in Parkinson's Disease
The purpose of this research study is to determine whether cognitive training will improve cognitive and brain functions in people with Parkinson's Disease (PD) during activities of daily living using cognitive evaluations and…
- Trial name
- NCT05495997
- Testing
- Mental Imagery Training, Psychoeducation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Yale University
Parkinson's Disease
High and Low Dose Carbidopa Treatment of Parkinson's Disease
Hypothesis: We hypothesize that carbidopa in daily doses of 450mg will enter the central nervous system and partially inhibit AAAD, thereby reducing the decarboxylation of exogenous levodopa to dopamine, and thereby blunt the…
- Trial name
- NCT01399905
- Testing
- carbidopa
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Oregon Health and Science University
Parkinson's Disease (PD)
A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)
The primary objective of this study was to examine the effect of levodopa-carbidopa intestinal gel (LCIG) compared with optimized medical treatment (OMT) on dyskinesia in participants with advanced Parkinson's disease (PD).
- Trial name
- DYSCOVER (NCT02799381)
- Testing
- Optimized antiparkinsonian treatment, Levodopa-Carbidopa Intestinal Gel (LCIG), CADD-Legacy ambulatory infusion pump
- Where
- 28 sites in United States, Finland and 5 more
- Volunteers
- 63 people
- Sponsor
- AbbVie
Parkinson's Disease
NET-PD LS-1 Creatine in Parkinson's Disease
The purpose of this trial is to determine if the nutritional supplement creatine slows the progression of Parkinson's disease over time.
- Trial name
- NCT00449865
- Testing
- creatine
- Where
- 50 sites in United States, Canada
- Volunteers
- 1,741 people
- Sponsor
- University of Rochester